• Pharmacology Consult
  • Cangrelor: Not the CHAMPION we hoped for

  • Cardiology Today, April 2014
    Sara Varnado, PharmD; Hasan Kazmi, PharmD; Danielle Blais, PharmD, BCPS
  • In the past decade, patient outcomes after PCI have improved considerably with the advent of the oral P2Y12 receptor antagonists clopidogrel, prasugrel...More »
  • Pharmacology Consult
  • The current status of amiodarone adverse event monitoring

  • Cardiology Today, December 2013
    Dave L. Dixon, PharmD, BCPS, CDE, CLS; Janice Kim, PharmD candidate
  • Amiodarone was discovered in 1961, but was not approved by the FDA until 1985. Although classified as a class III antiarrhythmic, amiodarone exhibits...More »
  • Pharmacology Consult
  • Oral agents in the treatment of PAH

  • Cardiology Today, November 2013
    Aileen Le, PharmD, BCPS; Jaekyu Shin, PharmD, MS, BCPS
  • Pulmonary arterial hypertension is characterized by elevated pulmonary pressures and increased pulmonary vascular resistance, eventually leading to...More »
  • Pharmacology Consult
  • Evaluation of chelation therapy for the treatment of CVD

  • Cardiology Today, October 2013
    Theresa Page, PharmD candidate; Cynthia Sanoski, PharmD, BCPS, FCCP
  • Use of chelation therapy as a treatment for CVD dates back to the 1950s. Chelation therapy uses a chelating agent to form complexes with multivalent...More »
  • Pharmacology Consult
  • Use of metformin in patients with diabetes and HF

  • Cardiology Today, August 2013
    Andrew J. Smith, PharmD, BCPS (AQ Cardiology); John D. Hill, PharmD candidate
  • Heart failure and type 2 diabetes are disease states that frequently coexist. Data from the IMPACT-HF registry demonstrated that more than 45% of patients...More »